A Randomized, Open Label, Single-Centre, Single-Dose, 4-Period, 4-Treatment Cross-over Study to Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) Under Fasting and Fed Conditions, to Compare to Intravenous Arsenic Trioxide, and to Evaluate Interaction with Calcium Carbonate in Patients with Acute Promyelocytic Leukemia.
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
100 Clinical Results associated with SDK Therapeutics, Inc
0 Patents (Medical) associated with SDK Therapeutics, Inc
100 Deals associated with SDK Therapeutics, Inc
100 Translational Medicine associated with SDK Therapeutics, Inc